GALDERMA
20.2.2020 09:02:05 CET | Business Wire | Press release
Galderma today announced that The New England Journal of Medicine (NEJM) has published full results from the Phase 2 study of its investigational therapy nemolizumab in adult patients suffering from moderate-to-severe prurigo nodularis (PN).
PN is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe pruritus. It frequently leads to a severe quality of life impairment. Nemolizumab is a first-in-class investigational monoclonal antibody that blocks signaling of IL-31 that play a key role in the pathogenesis of PN. Nemolizumab’s safety and efficacy have not been fully evaluated by any regulatory authority.
In this study, 70 patients with moderate to severe PN and severe pruritus were randomized to receive subcutaneous nemolizumab 0.5 mg/kg every 4 Weeks from baseline to Week 8 or matching placebo injections (at weeks 0,4 and 8). Nemolizumab met the primary endpoint of a greater improvement in Peak Pruritus Numerical rating scale (PP-NRS) from baseline to Week 4 compared to placebo. The baseline PP-NRS was 8.4 in both groups. At week 4, in nemolizumab arm PP-NRS was reduced from baseline by 4.5 (53.0%) compared to 1.7 (20.2%) in placebo; P<0.001. All the other measures showed a significant difference in patients taking nemolizumab. At week 18 (10 weeks after the last dose), 38 percent of the patients who received nemolizumab were clear or almost clear of PN compared to 6 percent of the patients who received placebo; P=0.001. Nemolizumab was well tolerated and no imbalance in adverse events was observed between the two groups. The full publication is available at https://www.nejm.org/doi/full/10.1056/NEJMoa1908316
“Prurigo nodularis is known to have a profoundly negative impact on quality of life of patients, and despite significant unmet needs, there are currently no registered therapeutic options” said Dr Thibaud Portal, Global Head of Prescription medicines at Galderma. “The Phase 2 study results indicate that nemolizumab may have a key role to play for patients with moderate to severe prurigo nodularis. We are fully committed to test this drug further in Phase 3 studies and determined to bring solutions for patients suffering from prurigo nodularis.”
“The New England Journal of Medicine publication brings important attention to prurigo nodularis, where it has been very challenging for clinicians to take care of their patients in the absence of any registered therapy targeting prurigo nodularis” said Sonja Ständer, M.D., Center for Chronic Pruritus, Department of Dermatology, University of Münster, Germany and lead author of the NEJM paper. “We are encouraged by the consistent findings across this study and look forward to further clinical investigation with nemolizumab.”
In November 2019, the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to the investigational therapy nemolizumab for the treatment of pruritus associated with PN. Galderma is actively preparing for the initiation of a Phase 3 pivotal program with nemolizumab in adult patients with PN in 2020.
About Nemolizumab
Nemolizumab, a first-in-class humanized monoclonal antibody, is directed against the IL-31 receptor alpha, which blocks signaling from IL-31. Nemolizumab, initially developed by Chugai Pharmaceutical Co., Ltd., was subsequently licensed to Galderma in 2016 – worldwide except Japan and Taiwan. Nemolizumab is an investigational agent under clinical development and its safety and efficacy have not been fully evaluated by any regulatory authority.
About Galderma
Galderma, the world's largest independent global dermatology company, was created in 1981 and is now present in over 100 countries with an extensive product portfolio of prescription medicines, aesthetics solutions and consumer care products. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit www.galderma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200220005309/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MetLife and Global Citizen Launch “Footwork for Futures” Social Media Challenge to Help Expand Access to Education and Sports12.5.2026 15:00:00 CEST | Press release
All donations will support the FIFA Global Citizen Education Fund, building on MetLife Foundation’s $9 million commitment Today, MetLife and Global Citizen announced Footwork for Futures, a global soccer-themed social media challenge that supports children’s access to quality education and sports to foster more confident and resilient communities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511913741/en/ Footwork for Futures invites people to share a short video of themselves juggling – or attempting to juggle – a soccer ball on Instagram, LinkedIn, X, TikTok, or Facebook and include the hashtag #FootworkForFutures, or by submitting a video through the Global Citizen app. For each eligible video submission, MetLife will donate $5 to the FIFA Global Citizen Education Fund, up to $100,000, to help support access to quality education and sports for children through grants to community-based organizations around the world.
Lenovo Enables One-Week Deployment of Production-Ready Agentic AI to Transform Enterprise Workflows12.5.2026 15:00:00 CEST | Press release
The Lenovo AI Library enables rapid deployment of prebuilt, industry-specific AI agents and use cases, aligned to enterprise workflows Delivered as part of Lenovo Hybrid AI Advantage™, enabling secure, governed AI deployment across hybrid environments Independently validated results show 30% productivity gains and up to 120 hours saved per employee annually Lenovo is enabling enterprises to deploy production-ready, agentic AI solutions in as little as one week1, eliminating the long development cycles that typically delay AI from reaching production, while maintaining enterprise-grade security, governance, and control. This is not theoretical, independent analysis from Signal65 confirms these results in real-world deployments. Lenovo’s Knowledge Super Agent reduced time spent on knowledge-related tasks by 30%, saving up to 120 hours per employee annually. In multiple deployments, organizations reached production up to 24× faster than with custom-built approaches, demonstrating how fast
Nikkiso Signs Agreement With Maran Tankers Management to Provide Aftermarket Service Support12.5.2026 15:00:00 CEST | Press release
Nikkiso Clean Energy & Industrial Gases Group (Nikkiso CE&IG) has announced today that it has signed a long-term service agreement with oil tanker shipping firm Maran Tankers Management Inc. Under the five-year agreement, Nikkiso CE&IG will deliver comprehensive global aftermarket support for Maran Tankers’ high pressure pumps, including scheduled cold end valve repairs at defined intervals. To guarantee minimal turnaround time, Nikkiso CE&IG will maintain critical inventory across its Marine Hubs worldwide, enabling cold ends to be received by vessels within days rather than the industry’s average of months. Nikkiso CE&IG will also provide technical guidance to Maran Tankers and carry out extended overhauls during scheduled dry-docking periods. Sean Fanniff, President of Nikkiso CE&IG’s Cryogenic Services Business Unit, said: “With Marine Hubs across Southeast Asia, Europe, the Middle East, the US, and China, we can provide our clients with a coordinated global approach and seamless p
Mixpanel Introduces Mixpanel AI, Delivering Always-On Product Intelligence12.5.2026 15:00:00 CEST | Press release
New AI agents, a business-aware Context Engine, and native integrations with Claude, Slack, and more help product teams instrument faster, diagnose issues in real time, and act with confidence Mixpanel, a global leader in product intelligence and analytics, today introduced Mixpanel AI — the always-on product intelligence system that helps teams ship faster and smarter by understanding how people use their products and what to do next. Unlike query-based analytics assistants, Mixpanel AI monitors your product continuously and surfaces insights and issues before teams think to ask, combining specialized AI agents, a business-aware Context Engine, and native integrations with the tools teams already use. Built on 17 years of product analytics infrastructure and trusted by more than 29,000 customers, Mixpanel AI turns product data into proactive, explainable intelligence that teams can act on — with the business context to make every answer relevant and the verified data foundation to mak
Introducing Cognite Flows™: The First Fully Integrated, AI-Native Industrial Experience that Accelerates Customer Value12.5.2026 15:00:00 CEST | Press release
Powered by Cognite’s industry-leading Industrial AI and Data Platform, Cognite Flows delivers the confidence and scalability needed to achieve outsized business impact from agentic AI Cognite, the global leader in Industrial AI, today announced Cognite Flows™, a new standard for industrial experiences that fundamentally redefines how teams engage with AI, apps, and data to address operational challenges. Designed to optimize the daily workflows of frontline teams, Cognite Flows puts everything they need—AI-driven insights and real-time data from multiple apps across every corner of the company—into an easily customized, single-screen workspace. For the first time in an industrial setting, software will adapt to the user, rather than the user needing to adapt to the software. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260512315975/en/ Introducing Cognite Flows™: The First Fully Integrated, AI-Native Industrial Experience
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom